torcetrapib has been researched along with Atherosclerosis in 46 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 32 (69.57) | 29.6817 |
2010's | 14 (30.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alaupovic, P; Bagdade, J; Barter, P; Quiroga, C | 1 |
Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F | 1 |
deGoma, EM; Rader, DJ | 1 |
Adam, LP; Bilder, D; Chang, M; Chen, AY; Chen, XQ; Finlay, HJ; Gordon, DA; Harikrishnan, LS; Huang, CS; Kamau, MG; Lawrence, RM; Leith, L; Levesque, P; Li, D; Li, J; Li, JP; Li, YX; Miller, MM; Poss, MA; Qiao, JX; Rampulla, R; Salvati, ME; Shen, H; Sleph, PG; Smith, D; Taylor, DS; Wang, TC; Wexler, RR; Wu, DR; Xu, C; Yang, RZ; Yin, X; Zhuang, S | 1 |
Quintão, EC | 1 |
Kastelein, JJ; Stroes, ES; van Leuven, SI | 1 |
Ahmed, MH | 1 |
Neeli, H; Rader, DJ | 1 |
Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL | 1 |
Pfeffer, MA; Sacks, FM | 1 |
Olsson, AG | 2 |
Feuerstein, G; Jin, W; Packard, C; Rader, D; Zhao, L | 1 |
Shinkai, H | 1 |
Stroes, ES; Vergeer, M | 1 |
Böhm, M; Laufs, U; Pöss, J | 1 |
Rizzoni, D; Rossi, GP | 1 |
Barter, PJ | 1 |
Mombelli, G; Sirtori, CR | 1 |
Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
Toth, PP | 1 |
Schaefer, JR | 1 |
Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A | 1 |
Kaski, JC | 1 |
Burnett, JR | 1 |
Barter, PJ; Kastelein, JJ | 1 |
Clark, RW | 1 |
El-Harchaoui, K; Kastelein, JJ; Kuivenhoven, JA; Van der Steeg, WA | 1 |
Chapman, MJ | 1 |
Davidson, MH; McKenney, JM; Revkin, JH; Shear, CL | 1 |
Ansell, B; Hobbs, FD | 1 |
Bourassa, PA; Gao, F; Milici, AJ; Morehouse, LA; Rothblat, GH; Sand, TM; Sugarman, ED; Zimetti, F | 1 |
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
Guo, CB; Li, S | 1 |
Opar, A | 1 |
Mazzone, T | 1 |
Suckling, K | 2 |
Orloff, DG | 1 |
Dueñas-Laita, A; Pérez-Castrillon, JL | 1 |
Hegele, RA; Joy, T | 1 |
Heinecke, JW; Oram, JF | 1 |
Conca, P; Franceschini, G | 1 |
de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M | 1 |
Duriez, P | 1 |
22 review(s) available for torcetrapib and Atherosclerosis
Article | Year |
---|---|
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia | 2014 |
Future of cholesteryl ester transfer protein inhibitors.
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2014 |
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds | 2016 |
High-density lipoprotein: a fall from grace?
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Humans; Quinolines | 2008 |
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines | 2008 |
Leapfrogging data: no shortcuts for safety or efficacy information.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Drug-Related Side Effects and Adverse Reactions; Humans; Quinolines | 2008 |
Is high HDL cholesterol always good?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Humans; Quinolines; Risk; Treatment Outcome | 2009 |
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Esters; Humans; Oxazolidinones; Patents as Topic; Quinolines; Sulfhydryl Compounds | 2009 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome | 2010 |
CETP Inhibition: does the future look promising?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Incidence; Male; Quinolines; Risk Factors | 2011 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Topics: Amides; Animals; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Esters; Glycoproteins; Humans; Quinolines; Risk Factors; Sulfhydryl Compounds; Vaccines | 2006 |
Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Female; Glycoproteins; Humans; Lipoproteins, HDL; Male; Quinolines; Sulfhydryl Compounds | 2006 |
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Glycoproteins; Humans; Models, Biological; Quinolines; Sulfhydryl Compounds | 2005 |
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Topics: Amides; Animals; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol, HDL; Coronary Disease; Esters; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; PPAR alpha; PPAR delta; PPAR gamma; Quinolines; Sulfhydryl Compounds | 2006 |
The potential for CETP inhibition to reduce cardiovascular disease risk.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines; Risk Factors; Vaccination | 2006 |
[Advances in the study of anti-atherosclerosis drugs].
Topics: Apolipoprotein A-I; Atherosclerosis; Benzoates; Benzylamines; Cholesterol Ester Transfer Proteins; DNA-Binding Proteins; Humans; Liver X Receptors; Molecular Structure; Orphan Nuclear Receptors; Oxazines; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Quinolines; Receptors, Cytoplasmic and Nuclear | 2007 |
Regulatory considerations in the development of high-density lipoprotein therapies.
Topics: Anticholesteremic Agents; Atherosclerosis; Biomarkers; Drug Approval; Humans; Lipoproteins, HDL; Quinolines | 2007 |
New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Macrophages; Quinolines | 2006 |
Is raising HDL a futile strategy for atheroprotection?
Topics: Amides; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Atherosclerosis; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Phospholipids; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2008 |
Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Humans; Quinolines | 2008 |
5 trial(s) available for torcetrapib and Atherosclerosis
Article | Year |
---|---|
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mineralocorticoids; Pyrroles; Quinolines | 2008 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Topics: Adult; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Double-Blind Method; Female; Humans; Male; Middle Aged; Quinolines | 2006 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
19 other study(ies) available for torcetrapib and Atherosclerosis
Article | Year |
---|---|
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial).
Topics: Anticholesteremic Agents; Apolipoprotein C-III; Apoproteins; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Quinolines; Retrospective Studies; Treatment Outcome | 2017 |
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Benzamides; Benzylamines; Blood Pressure; Cell Line; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cytochrome P-450 CYP11B2; Dogs; Drug Discovery; Humans; Macaca fascicularis; Male; Mesocricetus; Mice; Mice, Transgenic; Motor Activity; Quinolines; Rats; Rats, Sprague-Dawley | 2015 |
Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Humans; Quinolines | 2008 |
A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atheroscle
Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Drug Discovery; Forecasting; Humans; Lipid Metabolism; Quinolines; Risk Factors; Treatment Failure | 2009 |
Therapy: raising HDL cholesterol levels: a flight of Icarus?
Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines | 2010 |
The relationship between cholesteryl ester transfer protein and cardiovascular risk.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Genetic Predisposition to Disease; Humans; Polymorphism, Genetic; Quinolines; Risk | 2010 |
Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk | 2010 |
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds | 2012 |
HDL- cholesterol: a nut too hard to crack?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Niacin; Quinolines | 2012 |
Torcetrapib + atorvastatin (Pfizer).
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines | 2005 |
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Biological Transport; Cell Line, Tumor; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Susceptibility; Male; Quinolines; Rabbits; Regression Analysis | 2007 |
Where now for new drugs for atherosclerosis?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Humans; Quinolines | 2007 |
HDL cholesterol and atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Pyrroles; Quinolines; Tunica Intima | 2007 |
The continuing complexities of high-density lipoprotein metabolism in drug discovery and development.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Drug Design; Humans; Lipoproteins, HDL; Niacin; Quinolines | 2007 |
When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
Topics: Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Liver; Quinolines | 2007 |
Will CETP inhibition survive the demise of torcetrapib?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Quinolines; Risk Assessment; Risk Factors; Treatment Failure | 2008 |
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines | 2008 |
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines | 2008 |
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors | 2008 |